Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $124.15 Consensus Target Price from Brokerages

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received an average rating of “Hold” from the twenty-two ratings firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $124.15.

Several equities research analysts recently commented on ZBH shares. Raymond James decreased their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Royal Bank of Canada reduced their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. JMP Securities reiterated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus raised their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Finally, Truist Financial reiterated a “hold” rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th.

Zimmer Biomet Trading Down 0.7 %

NYSE:ZBH opened at $110.50 on Friday. Zimmer Biomet has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The firm’s fifty day moving average is $106.98 and its 200-day moving average is $106.90. The firm has a market cap of $22.00 billion, a P/E ratio of 24.83, a P/E/G ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company earned $2.20 EPS. Equities analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.95% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Stonebridge Financial Group LLC bought a new stake in Zimmer Biomet during the fourth quarter worth $25,000. Dunhill Financial LLC boosted its holdings in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the last quarter. Menard Financial Group LLC bought a new position in Zimmer Biomet during the fourth quarter valued at about $30,000. Brooklyn Investment Group purchased a new stake in Zimmer Biomet during the third quarter worth about $35,000. Finally, Accredited Wealth Management LLC bought a new stake in Zimmer Biomet in the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.